P/E - Molecular Partners AG (NASDAQ:MOLN) - Alpha Spread

Molecular Partners AG
NASDAQ:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
NASDAQ:MOLN
Watchlist
Price: 4.67 USD -3.51% Market Closed
Market Cap: 155m USD
Have any thoughts about
Molecular Partners AG?
Write Note

P/E
Price to Earnings

-1.9
Current
-1.4
Median
23.9
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-1.9
=
Market Cap
155m USD
/
Net Income
-69.1m CHF
All Countries
Close
Earnings Growth
CH
Molecular Partners AG
NASDAQ:MOLN
Average P/E: 57.6
Negative Multiple: -1.9
N/A
US
Abbvie Inc
NYSE:ABBV
64.6
406%
US
Amgen Inc
NASDAQ:AMGN
57.7
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.8
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -252.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
99.3
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.7 N/A
AU
CSL Ltd
ASX:CSL
36.7
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -485.3 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-2.3
2-Years Forward
P/E
-2.1
3-Years Forward
P/E
-1.8

See Also

Discover More